Competitive RisksThere are competitive risks, especially with respect to other checkpoint inhibitors, which could impact Tuhura Biosciences' market position.
Financial PerformanceTuHURA Biosciences reported a net loss of $0.21 per share—wider than previously estimated.
Regulatory ChallengesRisks include negative clinical results, delays, regulatory challenges, competitive risks, and long-term dilution risk.